Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

Summary

The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in patients with advanced solid malignancies.

Timeline

Start

2020-08-28

Primary completion

2024-11-22

Completion

2024-11-22

Outcome

Outcome not reported

Stopped (Business): “This decision is based on a strategic company decision to discontinue development of this program as part of our portfolio prioritization.”

Drugs

Indications

No indication recorded.